Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join Biosplice Therapeutics Board of Directors
2021年4月20日 - 9:45PM
Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage
biotechnology company pioneering therapeutics based on alternative
pre-mRNA splicing for major diseases, announced today the addition
of three independent directors to its board. New directors comprise
Troy Cox, former CEO of Foundation Medicine, Susannah Gray, former
EVP and CFO of Royalty Pharma Management, and Karen McGinnis,
former VP and CAO of Illumina.
“We are honored to have this caliber of experience and
leadership join our new board at Biosplice,” said Osman Kibar, PhD,
Founder and Executive Chairman of Biosplice. “Ms. Gray, Ms.
McGinnis, and Mr. Cox bring invaluable insight to our company as we
continue the buildout of our alternative splicing platform and
navigate the final stages of clinical development for our lead
osteoarthritis drug candidate, lorecivivint, and continue to
develop our promising oncology and neurology pipelines.”
Troy Cox led Foundation Medicine (NASDAQ: FMI), as President and
Chief Executive Officer, through the acquisition by Roche for $5.3
billion in 2018. Prior to Foundation Medicine, he served as Senior
Vice President and Officer at Genentech, where he led US
BioOncology for a period of unprecedented growth to over $12
billion while accountable to help steer the Roche Genentech R&D
portfolio. Before Genentech, Mr. Cox held executive and senior
roles, including President UCB BioPharmaceuticals, Senior Vice
President Sanofi-Aventis and diverse foundational roles at
Schering-Plough. He also currently serves as a director
of Zymeworks, Inc. (NYSE: ZYME), Sophia Genetics, LetsGetChecked,
CM Life Sciences II (NASDAQ: CMIIU) and MassBio.
Susannah Gray brings more than 30 years of biopharmaceutical
experience, specifically in corporate finance and capital markets
roles, most recently serving as Executive Vice President, Finance
& Strategy of Royalty Pharma Management, LLC. Ms. Gray also
spent 14 years as Executive Vice President and Chief Financial
Officer of Royalty Pharma before retiring in 2019.
Prior to joining Royalty Pharma, she had a 14-year career in
banking, working in various capacities within high yield and
structured finance departments of Chase Securities, Merrill Lynch
and CIBC World Markets. Ms. Gray also serves as a director of
Maravai LifeSciences (NASDAQ: MRVI) and 4D Molecular Therapeutics
(NASDAQ: FDMT).
Karen McGinnis has over 20 years of experience in executive
operational and finance roles at international public companies.
She most recently served as Vice President & Chief Accounting
Officer of Illumina, Inc. (NASDAQ: ILMN), a leader in sequencing-
and array-based solutions for genetic and genomic analysis. Earlier
in her career, Ms. McGinnis served as Director, President and Chief
Executive Officer, and previously Chief Financial Officer, of Mad
Catz Interactive, Inc. (OTC: MCZAF), a global provider of
innovative interactive entertainment products. Prior to joining Mad
Catz, Ms. McGinnis served as Chief Accounting Officer of Cymer,
Inc., a leading supplier to the semiconductor industry and,
previously, Chief Accounting Officer for Insight Enterprises, Inc.
Ms. McGinnis also currently serves as a director of Alphatec
Holdings, Inc. (NASDAQ: ATEC) and AbSci, Inc.
Learn more about Biosplice’s Board of Directors at
https://www.biosplice.com/board-of-directors
About BiospliceBiosplice is developing
first-in-class, small-molecule therapeutics based on pioneering
science of alternative pre-mRNA splicing. Stemming from
foundational discoveries in Wnt pathway modulation, Biosplice has
elucidated novel biology linking CLK/DYRK kinases to the
therapeutic regulation of alternative splicing. Alternative
splicing is an essential biological mechanism that regulates the
diversification of proteins in a cell, which, in turn, determines
cell type and function. Biosplice’s target class governs the
selection of tissue-specific mRNA splice sites, making them
attractive, druggable targets within the cellular “command and
control” center.
Biosplice’s drugs in clinical development include lorecivivint
for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers,
and a broad pipeline that ranges from Alzheimer’s disease to other
degenerative conditions. Learn more at
https://www.biosplice.com
Corporate Contact: Erich HorsleyBiosplice
Therapeutics, Inc.erich.horsley@biosplice.com858-365-0200
Foundation Medicine, Inc. (NASDAQ:FMI)
過去 株価チャート
から 11 2024 まで 12 2024
Foundation Medicine, Inc. (NASDAQ:FMI)
過去 株価チャート
から 12 2023 まで 12 2024